Clinical Study
Adjuvant Ciprofloxacin for Persistent BK Polyomavirus Infection in Kidney Transplant Recipients
Table 2
Management of BKV infection prior to addition of ciprofloxacin.
| ā | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 |
|
Time from transplant to BKV diagnosis (days) | 91 | 92 | 113 | 224 | 69 | 102 | 31 | 95 | 140 |
SCr at diagnosis (mg/dL) | 0.54 | 1.97 | 1.27 | 1.64 | 1.2 | 1.58 | 2.12 | 1.03 | 1.08 |
Viremia at diagnosis (copies/mL) | 903 | 2 * 106 | 78500 | 45300 | 31900 | 36200 | 49400 | 10700 | 500 |
Viruria at diagnosis (copies/mL) | 4600 * 106 | 4100 * 106 | 3000 * 106 | 1200 * 106 | 1700 * 106 | >500 * 106 | 116 * 106 | 170 * 106 | 5 * 106 |
Immunosuppression management prior to ciprofloxacin | MMF reduction, Tac to CsA | MMF stopped | MMF stopped, CsA reduction | MMF reduction, Tac reduction | MMF stopped, Tac to CsA | MMF stopped | MMF stopped | MMF reduction, Tac reduction | MMF stopped |
Cidofovir prior to ciprofloxacin | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Leflunomide prior to ciprofloxacin | No | No | No | No | Yes | No | No | No | Yes |
IVIG prior to ciprofloxacin | No | No | Yes | No | Yes | No | No | Yes | Yes |
Time from BKV diagnosis to ciprofloxacin (days) | 59 | 77 | 130 | 217 | 175 | 199 | 91 | 65 | 379 |
|
|
Abbreviations: BKV: BK polyomavirus; SCr: serum creatinine; IVIG: intravenous immunoglobulin; BKVAN: BK virus associated nephropathy; MMF: mycophenolate mofetil; Tac: tacrolimus; CsA: cyclosporine A.
|